Anika Therapeutics Is Maintained at Outperform by Barrington Research
Anika Therapeutics Analyst Ratings
Barrington Maintains Anika Therapeutics(ANIK.US) With Buy Rating, Cuts Target Price to $25
Barrington Maintains Anika Therapeutics(ANIK.US) With Buy Rating, Maintains Target Price $37
Analysts Are Bullish on Top Healthcare Stocks: Chromadex (CDXC), Anika Therapeutics (ANIK)
Anika Therapeutics Analyst Ratings
Barrington Research Maintains Outperform on Anika Therapeutics, Maintains $37 Price Target
Buy Rating Affirmed for Anika Therapeutics Amid Solid Financials and Strong Market Outlook
Anika Therapeutics Analyst Ratings
Barrington Research: Maintaining the Anika Therapeutics (ANIK.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $37.00 to $37.00.
Anika Therapeutics Analyst Ratings
Analysts Are Bullish on These Healthcare Stocks: Mineralys Therapeutics, Inc. (MLYS), Anika Therapeutics (ANIK)
Anika Therapeutics: Strong Q4 Performance and Upbeat FY2024 Outlook Justify Buy Rating and Raised Price Target
Anika Therapeutics Analyst Ratings
Barrington Research Maintains Outperform on Anika Therapeutics, Raises Price Target to $29
Anika Therapeutics Analyst Ratings
Anika Therapeutics Receives Buy Rating Based on Strong Q3 Performance and Positive 2023 Outlook
Anika Therapeutics (ANIK) Receives a Buy From Barrington
Anika Therapeutics Analyst Ratings
Stephens & Co. Maintains Equal-Weight on Anika Therapeutics, Lowers Price Target to $23